Novartis India Challenge Postponed To July 28/03/2012 by Intellectual Property Watch 2 Comments The Indian Supreme Court today postponed hearing the high-profile case involving Swiss pharmaceutical producer Novartis’ challenge of India’s patent law until July, according to sources.
UK Parliament Group Conducts Post-Hargreaves Inquiry Into IP Policy 22/03/2012 by Maricel Estavillo for Intellectual Property Watch 1 Comment The All-Party Parliamentary Intellectual Property Group in the United Kingdom is undertaking an inquiry into the government’s role in intellectual property (IP) promotion and protection, less than a year after the publication of an independent and comprehensive review on the UK’s IP system.
French IP Industry Experts Discuss IP Portfolios, Trademarks Online 21/03/2012 by Catherine Saez, Intellectual Property Watch Leave a Comment PARIS – Intellectual property assets and how they influence corporate value, plus trademarks in the digital world were discussed last week by intellectual property professionals gathered in Paris.
WIPO Design Treaty Proposal Still On Horizon; Key Points Bared 15/03/2012 by Maricel Estavillo for Intellectual Property Watch 1 Comment Members of the World Intellectual Property Organization (WIPO) are working to stage a diplomatic conference on the adoption of a new industrial design treaty at the earliest opportunity. The treaty, at the minimum, could harmonise certain aspects in design law, an area in intellectual property marked by stark differences in national procedures.
India Grants First Compulsory Licence, For Bayer Cancer Drug 12/03/2012 by Maricel Estavillo for Intellectual Property Watch 8 Comments In a move welcomed by many in the international community, India has granted an application, its first, from a homegrown generic drug maker to manufacture and sell a patented cancer drug under a compulsory licence.
European Parliament Hears Pitch For ACTA; But Did It Change Minds? 02/03/2012 by Dugie Standeford for Intellectual Property Watch 1 Comment The controversial Anti-Counterfeiting Trade Agreement consumed hours of European Parliament time this week as the European Commission sought to persuade lawmakers to approve it. But no matter how often EC officials, academics and lawyers said the treaty will not change EU law, scepticism still remains about its potential impact on digital freedoms and access to generic medicines in developing countries – including from the Parliament member who will author the legislative report.
Novartis Before India’s Supreme Court: What’s Really At Stake? 02/03/2012 by Rachel Marusak Hermann, Intellectual Property Watch 3 Comments As the Novartis Glivec patent case in India reaches the final phase of a long-running legal battle, there’s one point on which both the Swiss pharmaceutical company and its critics agree: the significance of this case goes far beyond the protection of a single medication.
Australian Tobacco Law May Head To WTO Dispute As TRIPS Council Meets 28/02/2012 by William New, Intellectual Property Watch 1 Comment The World Trade Organization committee responsible for intellectual property issues today is meeting to address its usual list of topics with two recent additions of international interest. Countries negotiating the embattled Anti-Counterfeiting Trade Agreement (ACTA) and a country opposed to Australia’s public health law on tobacco packaging have added these to the agenda. Sources at the meeting say opponents of the tobacco law may be near to filing a dispute settlement case at the WTO.
‘Balanced’ Copyright: Not A Magic Solving Word 27/02/2012 by Intellectual Property Watch 8 Comments It was obviously a moment of some embarrassment for the US Department of Commerce and the World Intellectual Property Organisation.
The Pulse Of IP In International Pharma Today 24/02/2012 by Rachel Marusak Hermann, Intellectual Property Watch Leave a Comment High-level policymakers, industry leaders, law professors and other stakeholders came together in Geneva recently to discuss the how the role of intellectual property is evolving when it comes to developing, protecting, and providing medicines.